Summary
My research interest focus on drug property evaluation, which involves the study of drug absorption, distribution, metabolism, excretion, and toxicity to identify the best candidates for developing novel successful drugs.
Education
Selected publications
Isoform Selectivities of Novel 4âHydroxycoumarin Imines as Inhibitors of Myosin II” J. Smith, J. Brawley, K.C. Bordenave, R. Olsen, A. Intasiri, C.R. Cremo, T.W. Bell, Eur. J. Med. Chem. 2023, 247:115008, 1-14.
“Reduction of Progranulin-Induced Breast Cancer Stem Cell Propagation by Sortilin-Targeting Cyclotriazadisulfonamide (CADA) Compounds” K. Berger, E. Pauwels, G. Parkinson, G. Landberg, T. Le, V.G. Demillo, L.A. Lumangtad, D.E. Jones, M.A. Islam, R. Olsen, T. Kapri, A. Intasiri, K. Vermeire, S. Rhost, T.W. Bell, J. Med. Chem. 2021, 64, 12865−12876.
“Synthesis and Evaluation of 4âHydroxycoumarin Imines as Inhibitors of Class II Myosins” J. Brawley, E. Etter, D, Heredia, A. Intasiri, K. Nennecker, J. Smith, B.M. Welcome, R.K. Brizendine, T.W. Gould, T.W. Bell, C. Cremo, J. Med. Chem. 2020, 63, 11131-11148.
“Syntheses and Anti-HIV and Human Cluster of Differentiation 4 (CD4) Down-modulating Potencies of Pyridine-fused Cyclotriazadisulfonamide (CADA) Compounds” L.A. Lumangtad, E. Claeys, S. Hamal, A. Intasiri, C. Basrai, E. Yen-Pon, D. Beenfeldt, K. Vermeire, T.W. Bell, Bioorg. Med. Chem. 2020, 115816. DOI: 10.1016/j.bmc.202.115816